DVAX insider trading
NasdaqGS HealthcareDYNAVAX TECHNOLOGIES CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About DYNAVAX TECHNOLOGIES CORP
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Company website: www.dynavax.com
DVAX insider activity at a glance
FilingIQ has scored 599 insider transactions for DVAX since May 27, 2015. The most recent filing in our index is dated Feb 10, 2026.
Across the full history, 10 open-market purchases
and 110 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DVAX insider trades is 66.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DVAX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading DVAX
Frequently asked
- How many insider trades does FilingIQ track for DVAX?
- FilingIQ tracks 599 Form 4 insider transactions for DVAX (DYNAVAX TECHNOLOGIES CORP), covering filings from May 27, 2015 onwards. 0 of those were filed in the last 90 days.
- Are DVAX insiders net buyers or net sellers?
- Across the full Form 4 history for DVAX, 10 transactions (2%) were open-market purchases and 110 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DVAX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is DVAX in?
- DYNAVAX TECHNOLOGIES CORP (DVAX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.82B.
Methodology & sources
Every DVAX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.